82 active not recruiting. 82 Phase 2, 15 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 82 | Active not recruiting 82 |
| Phase 1 | 15 | Active not recruiting 15 |
| Phase 3 | 6 | Active not recruiting 6 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS AS1986NS - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 1 / Phase 2 | Active not recruiting | Antelope Surgical Solutions, Inc | 15 | 2026-07-01 | 2026-10-16 |
| Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer 177Lu-P17-088 - Prostate Cancer | Phase 2 | Active not recruiting | First Affiliated Hospital of Fujian Medical University | 25 | 2026-04-29 | 2026-10-27 |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer BMS-986165, Degarelix - Prostate Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 7 | 2026-01-09 | 2026-10-05 |
| Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer 225Ac-LNC1011, 68Ga-PSMA-11 - Prostate Cancer | Phase 2 | Active not recruiting | First Affiliated Hospital of Fujian Medical University | 24 | 2025-04-22 | 2026-10-23 |
| EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Virginia | 60 | 2025-01-30 | 2026-04-27 |
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Darolutamide, Relugolix - Prostate Cancer, Advanced Prostate Cancer | Phase 2 | Active not recruiting | Atish Choudhury, MD | 33 | 2024-12-13 | 2026-03-09 |
| Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C) - High Risk Prostate Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | Ivan de Kouchkovsky, MD | 32 | 2024-12-09 | 2026-09-04 |
| High-Risk Metachronous Oligometastatic Prostate Cancer Trial niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT) - Prostate Cancer, Oligometastatic Disease | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 88 | 2024-04-17 | 2026-05-06 |
| Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors ACE-86225106 tablet - Solid Tumor, Adult, BRCA1 Mutation | Phase 1 / Phase 2 | Active not recruiting | Acerand Therapeutics (Shanghai) Limited | 298 | 2024-03-22 | 2026-08-04 |
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer Enoblituzumab, Standard of Care - Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 219 | 2024-02-16 | 2026-07-24 |
| Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy BioDFence G3 Placental Tissue Membrane, Robot-Assisted Radical Prostatectomy - Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy | Phase 2 | Active not recruiting | University of Miami | 118 | 2023-08-24 | 2026-07-14 |
| Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms Abiraterone - Usual, Abiraterone - Study - Prostate Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 600 | 2023-08-18 | 2026-06-10 |
| SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer Surgery alone, Peri-operative darolutamide + surgery. - Prostate Cancer | Phase 2 | Active not recruiting | Institut Claudius Regaud | 240 | 2023-08-10 | 2026-05-08 |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2023-02-14 | 2026-09-15 |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Olaparib, LHRH agonist - Prostate Cancer, BRCA1 Mutation | Phase 2 | Active not recruiting | Rana McKay, MD | 32 | 2023-02-01 | 2026-07-10 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer Lutetium-177 PSMA-I&T, Radium-223 - Metastatic Castration-resistant Prostate Cancer, MCRPC | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 36 | 2022-09-13 | 2025-02-07 |
| An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Acupuncture, Waitlist Control, Questionnaires - Survivorship, Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2022-09-09 | 2026-10-05 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Testosterone Undecanoate, Enzalutamide - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2022-03-07 | 2026-09-29 |
Showing 20 of 82. Sign in to see all of them.
Prostatic Neoplasms (82) · Breast Neoplasms (5) · Neoplasm Metastasis (3) · Bulbo-Spinal Atrophy, X-Linked (2) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Disease (1) · Endometrial Neoplasms (1) · Fatigue (1) · Glioblastoma (1)
Genital Diseases (82) · Genital Diseases, Male (82) · Genital Neoplasms, Male (82) · Male Urogenital Diseases (82) · Neoplasms by Site (82) · Prostatic Diseases (82) · Urogenital Diseases (82) · Urogenital Neoplasms (82) · Neoplasms (81) · Pathological Conditions, Signs and Symptoms (8) · Breast Diseases (5) · Pathologic Processes (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Neoplasms by Histologic Type (4)
enzalutamide (11) · Abiraterone Acetate (8) · Prednisone (8) · Androgen Antagonists (7) · Leuprolide (7) · Gonadotropin-Releasing Hormone (6) · abiraterone (6) · Radiotherapy (5) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (5) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (4) · Docetaxel (4) · Nivolumab (4) · Triptorelin Pamoate (4) · bicalutamide (4) · darolutamide (4)
Memorial Sloan Kettering Cancer Center (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · University of Wisconsin, Madison (4) · CHU de Quebec-Universite Laval (3) · Canadian Cancer Trials Group (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · University of Michigan Rogel Cancer Center (3) · AstraZeneca (2) · First Affiliated Hospital of Fujian Medical University (2) · Weill Medical College of Cornell University (2) · Acerand Therapeutics (Shanghai) Limited (1) · Antelope Surgical Solutions, Inc (1) · Astellas Pharma Global Development, Inc. (1)
United States (59) · Canada (12) · United Kingdom (8) · Australia (6) · China (6) · Spain (6) · France (5) · Belgium (4) · Italy (4) · Japan (4) · Netherlands (3) · South Korea (3) · Czechia (2) · Denmark (2) · Germany (2)
Daniel Gorovets, MD (3) · Kim Chi (3) · Jingsong Zhang, MD, PhD (2) · Peter L Choyke, M.D. (2) · Vincent Fradet, MD, PhD (2) · Weibing Miao, MD (2) · Aaron Hansen (1) · Abhishek Solanki, MD MS (1) · Abi Vainstein-Haras, MD (1) · Amado Zurita, MD (1) · Atish Choudhury, MD, PhD (1) · Bertrand Tombal, Pr (1) · Channing Paller, MD (1)
PMID 18990168, PMID 22452894, PMID 22747660, PMID 26718929, PMID 26719232, PMID 28300506, PMID 28578639, PMID 29321047, PMID 29528761, PMID 29529169, PMID 30355464, PMID 31560068, PMID 32203306, PMID 32398040, PMID 32994091, PMID 33036579, PMID 33270906, PMID 33386290, PMID 33568190, PMID 33599706, PMID 33632752, PMID 34757812, PMID 34953525, PMID 34961659, PMID 35153154, PMID 35405009, PMID 35446854, PMID 35671327, PMID 35715340, PMID 35929986, PMID 35984996, PMID 36059000, PMID 36465905, PMID 36639035, PMID 36710203, PMID 37012549, PMID 37142371, PMID 37178932, PMID 37608258, PMID 37787025, PMID 37821242, PMID 37973477, PMID 38101860, PMID 38229914, PMID 38421243, PMID 38421252, PMID 38519581, PMID 40339593, PMID 40467357, PMID 40539499
2016 (3), 2023 (2), 2004 (1), I01CX002277 (1), P30CA014089 (1), P30CA014520 (1), P50CA269011 (1), R01CA235032 (1)